New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 30, 2013
12:27 EDTAMGNEarnings Preview: Amgen shares up sharply in July ahead of Q2 results
Amgen (AMGN) is scheduled to report Q2 earnings after the market close on Tuesday, July 30, with a conference call scheduled for 5:00 pm ET. Amgen is an American-based multinational biopharmaceutical company headquartered in Thousand Oaks, California. EXPECTATIONS: Analysts are looking for EPS of $1.74 on revenue of $4.49B, according to First Call. The consensus range for EPS is $1.66-$1.83 on revenue of $4.35B-$4.57B. LAST QUARTER: Amgen reported Q1 EPS of $1.96 against estimates of $1.84 on revenue of $4.2B, against estimates of $4.37B. STREET RESEARCH: On May 1, Amgen was upgraded to Conviction Buy from Neutral at Goldman. Goldman upgraded Amgen based on valuation and its late-stage pipeline which is highly innovative and has the potential to replace key biologic franchises that are coming off patent. Goldman raised its price target to $130 from $100 on Amgen shares. PRICE ACTION: Amgen shares have rallied approximately 15% since early July and are up 0.9% on the day to $110.35
News For AMGN From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
April 17, 2015
09:20 EDTAMGNInsulet weakness creates buying opportunity, says Wedbush
Wedbush believes that Insulet's growth should accelerate as the year progresses, driven by increased adoption of its unique, programmable insulin pump and the launch of Amgen's (AMGN) Neulasta On-Body Delivery System.
April 15, 2015
18:56 EDTAMGNOn The Fly: After Hours Movers
Subscribe for More Information
17:06 EDTAMGNAmgen confirms FDA approval of Corlanor
Subscribe for More Information
16:40 EDTAMGNFDA approves Amgen's Corlanor to treat heart failure
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use